5728 Federal Register / Vol. 72, No. 25 / Wednesday, February 7, 2007 / Notices 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. 

Inventors: Suresh K. Arya (NCI). 

Publication: SK Arya et al. Human 

immunodeficiency virus type 2 

lentivirus vectors for gene transfer: 

expression and potential for helper 

virus-free packaging. Hum Gene Ther. 

1998 Jun 10;9(9):1371–1380. 

Patent Status: U.S. Patent No. 

6,790,657 issued 14 Sep 2004, entitled 

‘‘Lentivirus Vector System’’ (HHS 

Reference No. E–231–1998/0-US–03); 

U.S. Patent Application No. 10/731,988 

filed 09 Dec 2003, now allowed, entitled 

‘‘Lentivirus Vector System’’ (HHS 

Reference No. E–231–1998/0-US–04). 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: David Lambertson, 

Ph.D.; 301/435–4632; 

lambertsond@od.nih.gov. 

Methods and Compositions of 

Chemokine-Tumor Antigen Fusion 

Proteins as Cancer Vaccines 

Description of Technology: Tumor 

cells are known to express tumor 

specific antigens on the cell surface. 

These antigens are believed to be poorly 

immunogenic, largely because they 

represent gene products of oncogenes or 

other cellular genes which are normally 

present in the host. As a result, poor 

immunogenicity of relevant cancer 

antigens has proven to be a major 

obstacle to successful immunotherapy 

with tumor vaccines. Thus, there is a 

need for a more potent vaccine to elicit 

an immune response effective in the 

treatment or prevention of cancer. 

The current invention embodies a 

fusion protein comprising of a 

chemokine and tumor antigen. The 

inventors reported in several peerreviewed manuscripts that these fusion 

proteins represent potential vaccines for 

use against cancer. More specifically, 

the inventors have developed a vaccine 

construct that expresses fusion protein 

comprising human monocyte 

chemotactic protein-3 fused with tumor 

antigens, such as lymphoma-derived Id 

or breast cancer Muc-1. Administration 

of the fusion protein, or a nucleic acid 

encoding the fusion protein, elicits a 

specific immune response directed 

against the tumor antigen or protein, 

thereby inhibiting the growth of cells 

expressing this antigen or protein. 

Applications and Modality: Potential 

immunotherapy for cancer. 

Market: 600,000 deaths from cancer 

related diseases estimated in 2006. 

Development Status: This technology 

is currently in the pre-clinical stage of 

development. 

Inventors: Larry Kwak (NCI) and Arya 

Biragyn (NIA). 

Patent Status: U.S. Patent No. 

6,562,347 issued 13 May 2003 (HHS 

Reference No. E–107–1998–0-US–03). 

Licensing Status: Available for 

exclusive and non-exclusive licensing. 

Licensing Contact: Jennifer Wong; 

301/435–4633; wongje@mail.nih.gov. 

Dated: January 31, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–1931 Filed 2–6–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Cancer Institute Board of 

Scientific Advisors. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: National Cancer 

Institute Board of Scientific Advisors. 

Date: March 5–6, 2007. 

Time: March 5, 2007, 8 a.m. to 6 p.m. 

Agenda: Director’s Report: Ongoing and 

New Business; Reports of Program Review 

Group(s); and Budget Presentation; Reports of 

Special Initiatives; RFA and RFP Concept 

Reviews; and Scientific Presentations. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 10, Bethesda, MD 20892. 

Time: March 6, 2007, 8 a.m. to 1 p.m. 

Agenda: Reports of Special Initiatives; RFA 

and RFP Concept Reviews; and Scientific 

Presentations. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 10, Bethesda, MD 20892. 

Contact Person: Paulette S. Gray, PhD, 

Executive Secretary, Director, Division of 

Extramural Activities, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Rm. 8001, 

Bethesda, MD 20892, 301–496–5147, 

grayp@mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH as instituted 

stringent procedures for entrance onto the 

NIH campus. All visitor vehicles, including 

taxicabs, hotel, and airport shuttles will be 

inspected before being allowed on campus. 

Visitors will be asked to show one form of 

identification (for example, a governmentissued photo ID, driver’s license, or passport) 

and to state the purpose of their visit. 

Information is also available on the 

Institute’s/Center’s home page: 

deainfo.nci.nih.gov/advisory/bsa.htm, where 

an agenda and any additional information for 

the meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: January 31, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–519 Filed 2–6–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel, 

Research Project in Cardiothoracic Surgery. 

Date: March 7–8, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Georgetown, 2101 

Wisconsin Avenue, NW., Washington, DC 

20007. 

Contact Person: Shelly S. Sehnert, PhD., 

Scientific Review Administrator, Review 


sroberts on PROD1PC70 with NOTICES